Month: September 2026

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos Growing Company Inc. Kingsville location.  
  
Presentation materials can be accessed on the Company’s Investor Relations website under Events & Presentations at: https://ir.thecronosgroup.com/events-presentations

The session will be webcast today starting at 12:00 p.m. ET. Webcast registration is now open at: https://dpregister.com/sreg/10211885/104dd78be04.

After the event, a recording of the webcast will be archived for replay on the Company’s website at: https://ir.thecronosgroup.com/events-presentations, and available for 12 months thereafter. 

About Cronos 
Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach^®, PEACE NATURALS^®, LIT™ and Lord Jones^®. For more information about Cronos and its brands, please visit: thecronosgroup.com. 

For further information, please contact:   
  
Media Relations Contact:   
Emily Whalen   
Communications   
Tel: (416) 504-0004   
media.relations@thecronosgroup.com  
  
Investor Relations Contact:  
Harrison Aaron   
Investor Relations   
Tel: (416) 504-0004   
investor.relations@thecronosgroup.com  

To Benefit Select Ronald McDonald House Chapters in the U.S.

LITTLE ROCK, Ark., Sept. 24, 2026 (GLOBE NEWSWIRE) — (NYSE: DDS) Dillard’s is pleased to further its commitment to Ronald McDonald House® with Dillard’s 32^nd annual holiday fundraiser. Since 1994, Dillard’s has supported Ronald McDonald House families with a fundraiser benefiting select Chapters across the United States.

The Southern Living Christmas Cookbook benefiting Ronald McDonald House^® is now available exclusively at Dillard’s.

Create some magic with this all-new cookbook from Southern Living, featuring inventive recipes and holiday decorating ideas. Find inspiration from Southern Living stylists using pieces from the Southern Living Home Collection, exclusively at Dillard’s. With 100+ brand-new recipes and 115+ full-color photos throughout, this Christmas 2026 cookbook is the must-have resource for entertaining with elegance and ease this holiday season.

The cookbook is available now in all Dillard’s stores nationwide and online at dillards.com for just $15. Profits from the sale of the cookbook will benefit select Ronald McDonald House Chapters in Dillard’s markets in the U.S.

“In 2026, Ronald McDonald House provided more than 2.9 million overnight stays for families with children who are ill or injured around the world,” said Lauren Biedron, Global Chief Philanthropy Officer at Ronald McDonald House. “We’re incredibly grateful for Dillard’s continuous support of our mission through the sale of their Southern Living Christmas Cookbook.”

Now in its 32^nd year of support, Dillard’s has raised more than $16.3 million to benefit Ronald McDonald House. “Our continued relationship with Ronald McDonald House gives all of us at Dillard’s an enormous sense of pride. We look forward to another successful fundraiser this year and are honored to support Ronald McDonald House programs in our communities,” said Denise Mahaffy, Senior Vice President of Dillard’s.

Ronald McDonald House is an independent, nonprofit 501(c)(3) organization that cares for families when they have children who are ill or injured. Through a global network of 250 independently operated Chapters in more than 60 countries and regions, we surround families with the resources, services, and support they need, removing barriers so they can be at the heart of their child’s care and ensure the best possible health outcomes. For more information, visit ronaldmcdonaldhouse.org.

Dillard’s was founded by William T. Dillard in 1938 in Nashville, Arkansas, with an $8,000 investment in a hometown department store. Today, Dillard’s, Inc. ranks among the nation’s largest fashion retailers – operating 272 Dillard’s stores, including 28 clearance centers, spanning 30 states and an Internet store at dillards.com. The Company focuses on delivering style, quality, and value to its customers by offering premium fashion apparel, beauty, and home collections from national and exclusive brand sources. Dillard’s complements this curated product assortment with exceptional, client-focused customer care.

CONTACT:
Julie Guymon
Dillard’s
501.376.5965
julie.guymon@dillards.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8a37c2e5-bdbd-4d2e-865d-7a39bfaa9b0e

Proposed Transaction Contemplates Strategic Combination Designed to Expand NGCG’s International Growth Opportunities in the Natural Resources Sector

SCOTTSDALE, Ariz., Sept. 24, 2026 (GLOBE NEWSWIRE) — New Generation Consumer Group, Inc. (OTC: NGCG), a leader in technology-driven infrastructure and scalability solutions, today announced that it has entered into a Letter of Intent (“LOI”) with Nutrien Mineral Limited, a Uganda-based mineral development company, regarding a proposed strategic business combination and reverse merger transaction.

The non-binding LOI establishes a framework for both parties to conduct reciprocal due diligence and negotiate definitive agreements related to a potential transaction designed to create a combined publicly traded enterprise under the NGCG platform.

Under the preliminary terms of the LOI, the parties are evaluating a transaction structure whereby NGCG would hold a proposed 51% ownership interest in the agreed transaction structure or combined business vehicle. The contemplated structure is intended to facilitate the consolidation and reporting of the combined business through NGCG’s public company reporting framework.

As part of the proposed transaction, Nutrien Mineral Limited would receive 5% of the issued and outstanding common shares of NGCG, subject to satisfactory due diligence, valuation review, regulatory compliance, and execution of definitive agreements. Additional provisions contemplate Nutrien Mineral Limited’s participation in future capital raises dedicated to supporting the growth and development of the combined enterprise.

The parties have agreed to cooperate in the exchange of audited financial statements and other legal, operational, technical, and corporate information necessary to evaluate the transaction and complete a comprehensive due diligence process.

CEO Commentary

Jacob DiMartino, Chief Executive Officer of New Generation Consumer Group, Inc., stated:

“We believe this proposed partnership with Nutrien Mineral Limited has the potential to position NGCG at the forefront of a significant international growth opportunity. As we continue to build shareholder value, we are focused on identifying transactions that can provide meaningful asset-backed expansion, expanded revenue potential, and long-term scalability. Nutrien’s opportunities within the mineral sector align with our vision for strategic diversification, and we look forward to conducting due diligence as we work toward a definitive agreement that benefits both organizations and our shareholders.”

Next Steps

The proposed transaction remains subject to, among other things:

• Completion of satisfactory reciprocal due diligence;
• Negotiation and execution of definitive agreements;
• Board and shareholder approvals, where required;
• Compliance with applicable legal and regulatory requirements; and
• Satisfaction of customary closing conditions.

There can be no assurance that the parties will enter into definitive agreements or that any transaction contemplated by the LOI will ultimately be completed.

The team at New Generation Consumer Group, Inc., would like to express their sincere gratitude to TradePro Securities for the introduction to Nutrien Mineral Limited.

About New Generation Consumer Group, Inc.

New Generation Consumer Group, Inc. (OTC: NGCG) is focused on identifying and developing scalable revenue-generating business opportunities across emerging technology sectors, with a strategic emphasis on artificial intelligence infrastructure and digital platforms.

About Nutrien Mineral Limited

Nutrien Mineral Limited is a Uganda-based mineral company engaged in the exploration, development, and commercialization of mineral-related opportunities within East Africa.

Safe Harbor / Forward-Looking Statements

​This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements can be identified by the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance,” “future,” or similar expressions. These statements, including those regarding the closing of the Reg A offering, securing private lender financing, pending and future acquisitions of app-based companies, future profitability, and plans to uplist to a senior exchange, are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially due to various factors, including market conditions, the company’s ability to successfully negotiate and close private financing or acquisitions, and general economic conditions. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT:

Investor Relations

New Generation Consumer Group Inc.

Phoenix, Arizona

Email: InvestorRelations@ngcg.com

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — SkyAI, Inc. (Nasdaq: SKYA) (“SkyAI” or the “Company”) today issued the following statement regarding the voting results at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”).

The SkyAI Board of Directors (the “Board”) recognizes that the Annual Meeting voting results reflect significant concerns among our shareholders, and we take that message seriously. The Board and management are committed to listening carefully, understanding those concerns, and responding constructively.

Informed by our ongoing engagement with shareholders, the Board and management are evaluating actions across capital allocation, corporate governance, and strategic direction. We are also evaluating opportunities to strengthen our communications and engagement with shareholders. The goal of this work is to narrow the discount of the Company’s share price to NAV and enhance value for shareholders.

We look forward to providing an update on our efforts in the coming weeks.

Voting results from the Annual Meeting will be available in the Company’s Form 8-K to be filed with the U.S. Securities and Exchange Commission.

About SkyAI
SkyAI, Inc. (Nasdaq: SKYA), a Solana digital asset treasury, is building a financial platform that will combine stablecoin rails on Solana with AI. For additional information, please visit www.skyai.co.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this release other than statements of historical fact are forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and beliefs, and involve risks and uncertainties that could cause actual results to differ materially.

These risks and uncertainties include, among others: the Company’s ability to successfully execute its Solana treasury strategy; the Company’s ability to successfully execute its AI technology strategy; volatility in the market price of SOL and other digital assets; changes in the regulatory or legal environment; competitive pressures; and general market, economic, and business conditions. Additional risks are described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov. 

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise these statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Contact

Media Contact
Edelman Smithfield
SkyAI@edelmansmithfield.com

• Group-wide activity integrates advisory, regulatory and methodological expertise across Diginex products and solutions
• Under the leadership of new interim CEO, Archana Kotecha, the intention is to turn insight into practical action and ultimately help clients achieve better, measurable outcomes.
• Johannes Weber named VP of Sustainability Science and Intelligence

LONDON, Sept. 24, 2026 (GLOBE NEWSWIRE) — Diginex Limited (NASDAQ: DGNX) (“Diginex” or the “Company”), a leading provider of Sustainability RegTech solutions, today announced the consolidation of a new, Group-level Subject Matter Expertise (“SME”) Group, bringing together the Company’s scientific, regulatory and methodological expertise to support product development and advisory delivery in order to help clients move from information to insights, leveraging data to drive measurable outcomes and improve performance.

The initiative marks a continued step in Diginex’s business integration strategy, aimed at delivering best-in-class solutions. It extends the integration mandate Archana Kotecha carried as Chief Impact Officer, when she was tasked with bringing the Diginex, Plan A, Matter and The Remedy Project offerings together into unified commercial solutions. Since being appointed interim Chief Executive Officer on August 31, 2026, Ms. Kotecha has moved to build that mandate into a clearer, Group-level capability.

A Group-Wide Initiative for ESG Intelligence, Product Development and Advisory

The SME Group will operate across three core pillars:

Science & Intelligence: bringing together scientific, regulatory and methodological expertise to inform Diginex’s solutions and help translate complex sustainability requirements into actionable intelligence.

Products & Upgrades: embedding subject-matter expertise into product development, methodologies, data logic and future product enhancements.

Advisory Services: applying the Group’s combined expertise to practical client solutions across environmental and human rights challenges, enabling its clients to take strategic and financial decisions based on the data its tools provide.

Johannes Weber has been appointed VP of Sustainability Science and Intelligence.

Johannes Weber is an environmental management and sustainability professional with 14 years of international affairs and business experience advising ministerial and C-level decision-makers at the intersection of innovation and sustainable development.

Prior to his appointment as VP, Sustainability Science and Intelligence at Diginex, he served as the Director of Sustainability Solutions at Plan A in Berlin, where he was responsible for developing the company’s carbon accounting capabilities and advisory services. Prior to his role at Plan A, Johannes was Head of Global Sustainability at Bird Rides. He also spent nearly a decade at the OECD in Paris, where he delivered strategic recommendations to national governments to accelerate green technology uptake and sustainable urban infrastructure.

Management Commentary

“As Chief Impact Officer, I began the work of connecting our expertise more intentionally, ensuring that our products and advisory services draw on the depth of scientific, regulatory and specialist knowledge across the Group. Establishing this as a clearer, Group-level capability is a natural next step,” said Archana Kotecha, Interim Chief Executive Officer of Diginex. “By bringing our scientific, regulatory, and specialist expertise closer to how we develop our products and deliver for clients, we can strengthen our methodologies, turn insight into practical action and ultimately help our clients achieve better, measurable outcomes.”

“I am pleased to take on this role at a moment when clients need scientific and regulatory expertise translated into practical, day-to-day decisions,” said Johannes Weber, VP of Sustainability Science and Intelligence at Diginex. “Our focus in Science & Intelligence is to make sure that expertise doesn’t sit apart from the business; it should shape how our products are built and how our advisory teams support clients on ESG and human rights challenges.”

About Diginex

Diginex Limited (NASDAQ: DGNX) (“Diginex” or the “Company”) is a London-headquartered RegTech business, providing ESG, sustainability and compliance solutions through an integrated platform trusted by global enterprises and financial institutions.

Its portfolio of products and services spans the full sustainability lifecycle, including Diginex ESG (reporting), Plan A (carbon accounting), Matter (data and investment intelligence), Lumen (supply chain risk and traceability), Apprise (worker voice), and The Remedy Project (human rights remediation), combining technology, analytics and advisory services to turn verified data into decision-ready business intelligence.

For more information, please visit the Company’s website: https://www.diginex.com/

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including statements regarding leadership transition and integration of recently acquired businesses. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the parties to consummate the proposed transaction; satisfaction of closing conditions to the consummation of the proposed transaction; the impact of the announcement of the proposed transaction on the Company’s relationships with its employees, existing customers or potential future customers, and the risk factors described in the Company’s 2026 Annual Report on Form 20-F filed with the SEC on August 13, 2026. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events, except as required by law.

Investor Relations

Email: ir@diginex.com
IR Contact – US
Jackson Lin
Lambert by LLYC
Phone: +1 (646) 717-4593
Email: jian.lin@llyc.global

Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil

MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Montreal Heart Institute, recently activated as the first Canadian clinical trial site for the ReVeRA-301 Phase 3 pivotal trial evaluating etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR), has enrolled their first patient. The expansion into Canada advances the multinational study toward its target of 150 patients with treated AFib-RVR events. ReVeRA-301 is evaluating the same 70 mg repeat-dose regimen that is U.S. Food and Drug Administration (FDA)-approved for paroxysmal supraventricular tachycardia (PSVT) as CARDAMYST® (etripamil) nasal spray.

“Activating clinical trial sites and enrolling study participants in Canada are important steps toward advancing ReVeRA-301 and reflect the momentum behind our global enrollment efforts following the recent first enrolled patient in the United States,” said David Bharucha, M.D., PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals. “We are honored to continue our work with the strong Canadian community of cardiovascular investigators and centers with deep experience in atrial fibrillation research.”

“Following the promising Phase 2 data, we are pleased to advance etripamil into this pivotal Phase 3 trial in AFib-RVR,” said Adrian Petzl, M.D., Cardiologist-Electrophysiologist, Montreal Heart Institute, and investigator on ReVeRA-301. “The ability to intervene promptly with a self-administered therapy outside of the emergency department could represent a meaningful change for patients living with this condition. We are excited that the Montreal Heart Institute is at the forefront of this global research initiative.”

About ReVeRA-301

ReVeRA-301 is a Phase 3 multinational, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil nasal spray in approximately 150 patient events with AFib-RVR. Prompted by symptoms, patients will self administer, in a medically unsupervised setting (e.g., at home), the same 70 mg dose of etripamil and repeat-dose regimen that supports the current FDA indication for the treatment of PSVT. Based on safety data demonstrated to date, Milestone is currently pursuing a single-study supplemental new drug application (sNDA) registration pathway for the treatment of AFib-RVR. The primary endpoint for ReVeRA-301 is reduction in ventricular rate (VR) within 30 minutes. The study will also evaluate a key secondary endpoint of symptom improvement via patient-reported outcomes. Clinical trial sites and enrollment information can be found at https://clinicaltrials.gov.

The trial advances research from ReVeRA-201, a multi-center Phase 2, randomized controlled study of the efficacy and safety of etripamil nasal spray for the acute reduction of symptomatic AFib-RVR in an emergency room setting. The clinical trial showed that a single dose of etripamil nasal spray at 70 mg reduced VR and improved both relief of symptoms and treatment satisfaction.

About Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

Atrial fibrillation (AFib) is the most common sustained arrhythmia, affecting over 6 million people in the United States. The prevalence of AFib in Canada is similarly problematic to that in the United States. The Canadian Cardiovascular Society estimates that AFib affects approximately 1-2% of the population, up to approximately 800,000 people in Canada, and represents a substantial and growing public health burden. AFib presents with an irregular heart rate and is classified as paroxysmal, persistent, or permanent. When there is a rapid heart rate during AFib, it is referred to as “atrial fibrillation with rapid ventricular rate (AFib-RVR).”

Market research indicates that 30-40% of patients with AFib experience at least one episode of RVR per year requiring urgent medical attention. These episodes commonly cause palpitations, shortness of breath, and weakness. While AFib is rarely life-threatening, it is a serious condition that often requires treatment and increases the risk of serious complications if not properly managed. Current options for acute AFib-RVR management are limited and often involve an emergency department visit for IV beta blockers, IV calcium channel blockers, or electrical cardioversion.

About CARDAMYST in the United States

CARDAMYST^® (etripamil) nasal spray is approved by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a novel calcium channel blocker nasal spray designed as a self-administered rapid response therapy for patients, thereby bypassing the need for immediate medical oversight. The product is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT. Currently, etripamil is in Phase 2 development for treatment of PSVT in pediatric patients and Phase 3 development for control of acute atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults. For more information, please visit CARDAMYST.com.

U.S. FDA Indication
CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

IMPORTANT SAFETY INFORMATION FOR CARDAMYST (etripamil)

What is CARDAMYST?

CARDAMYST is a prescription medicine used to help restore normal sinus heart rhythm in adults who have symptoms of sudden episodes of fast heartbeat called paroxysmal supraventricular tachycardia (PSVT).

It is not known if CARDAMYST is safe and effective in children.

Do not use CARDAMYST if you:

• are allergic to CARDAMYST or any of its ingredients. See the Patient Information for a complete list of ingredients in CARDAMYST.
• have limitations in activities due to heart failure (moderate to severe heart failure).
• have Wolff-Parkinson-White (WPW) syndrome, Lown-Ganong-Levine syndrome, or an abnormal heart rhythm pattern called pre-excitation (delta wave) on an electrocardiogram (ECG).
• have sick sinus syndrome without a permanent pacemaker.
• have second degree or higher atrioventricular (AV) block.

Before using CARDAMYST, tell your healthcare provider about all of your medical conditions, including if you:

• have a history of fainting.
• have low blood pressure.
• are pregnant or plan to become pregnant. It is not known if CARDAMYST will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if CARDAMYST passes into your breast milk. You should stop breastfeeding for 12 hours after treatment with CARDAMYST. During this time, pump and throw away your breast milk. Talk to your healthcare provider about the best way to feed your baby after using CARDAMYST.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of CARDAMYST?

CARDAMYST may cause serious side effects, including:

• Fainting due to CARDAMYST effects on blood pressure, heart rate, and electrical activity of the heart. CARDAMYST may cause dizziness and fainting, especially in people with a history of fainting and certain heart problems, or people with a history of fainting during an episode of PSVT. Use CARDAMYST while sitting in a safe area where you will not fall if you become dizzy or lightheaded. Lie down if you feel dizzy or lightheaded after using CARDAMYST. If fainting occurs after using CARDAMYST, caregivers should place you on your back and seek medical help.

The most common side effects of CARDAMYST include:

nasal discomfort nasal congestion runny nose

throat irritation nosebleed

These are not all of the possible side effects for CARDAMYST. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information 
https://milestonepharma.com/etripamilprescribinginformation.pdf for CARDAMYST.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding: Milestone’s business strategy and plans; the design, timing, and enrollment of the ReVeRA-301 Phase 3 clinical trial for AFib-RVR, including the anticipated number of patients and sites; the potential for etripamil to serve as a treatment option for patients with AFib-RVR, including as a self-administered therapy; the commercialization and market adoption of CARDAMYST; the development of etripamil for additional indications, including Phase 2 development in pediatric PSVT patients; expectations regarding the efficacy and safety of etripamil for AFib-RVR based on Phase 2 findings; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the FDA; and other statements not related to historical facts. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of Milestone’s clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs and conflicts, and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related to the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2025, under the caption “Risk Factors,” as such discussions may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com

Media Relations
Rebecca Novak, rnovak@milestonepharma.com 

Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP)

Anticipated initiation of Phase 2 trial in mid-2027

VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci’s generative AI platform, for endometriosis.

The planned Phase 2, double-blind, randomized, placebo-controlled trial would assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain as reported via patient-reported measures. For this trial, Absci anticipates recruiting approximately 150 patients from approximately 10 or more countries, subject to protocol finalization and regulatory clearance.

“Endometriosis affects roughly one in ten women of reproductive age, often leading to debilitating and life-altering pain. We are developing ABS-201 because we believe prolactin receptor blockade offers a fundamentally different, non-hormonal approach that may fulfill the substantial unmet clinical need facing these patients,” said Ransi Somaratne, MD, Chief Medical Officer, Head of R&D. “The initiation of this Phase 2 trial would be an important step toward establishing ABS-201’s ability to deliver durable relief of endometriosis-associated pain with a differentiated safety and tolerability profile.”

With the safety, tolerability, and pharmacokinetic (PK) data being generated for ABS-201 in the company’s ongoing HEADLINE™ trial, Absci anticipates initiation of this Phase 2 clinical trial for endometriosis in mid-2027. Absci is designing STORYLINE as a dose-ranging trial, anticipating testing two or three dose levels that will be confirmed following review of HEADLINE data.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for pattern hair loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: the development and clinical progress of Absci’s pipeline programs, including ABS-201; the design, enrollment, conduct, and timelines of our ongoing Phase 1/2a HEADLINE™ clinical trial of ABS-201 for pattern hair loss and the data being generated therefrom; the anticipated use of safety, tolerability, and pharmacokinetic data from the HEADLINE trial to inform dose selection for the STORYLINE™ clinical trial, including the anticipated testing of two or three dose levels pending review of such data; the planned design, patient enrollment targets, dosing strategy, country participation, and efficacy and safety endpoints of the Phase 2 STORYLINE trial of ABS-201 for endometriosis; the anticipated initiation of the STORYLINE trial in mid-2027, subject to regulatory clearance and protocol finalization; the potential for ABS-201 to provide efficacy in reducing endometriosis-associated pain and a differentiated safety and tolerability profile; the potential advancement of ABS-201 into Phase 3 development; the anticipated characteristics and product profile of ABS-201 as a drug product and its ability to fulfill unmet clinical need in endometriosis; and potential market opportunity and commercial prospects for ABS-201. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in Absci Corporation’s most recent annual report on Form 10-K and in any subsequent filings made by Absci Corporation with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Absci® standard character mark, ABS-201™, STORYLINE™, HEADLINE™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com

Media Contact
press@absci.com

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — Getty Realty Corp. (NYSE: GTY), a net lease REIT focused on convenience and automotive retail real estate, will release its financial results for the third quarter ended September 30, 2026 after the market closes on Wednesday, October 21, 2026.

Getty Realty Corp. will host a conference call and webcast on Thursday, October 22, 2026, at 8:30 a.m. ET. To participate in the call, please dial 1-877-423-9813, or 1-201-689-8573 for international participants, ten minutes before the scheduled start. Participants may also access the call via live webcast by visiting the investors section of the Company’s website at ir.gettyrealty.com.

If you cannot participate in the live event, a replay will be available on Thursday, October 22, 2026, beginning at 11:30 a.m. ET through 11:59 p.m. ET, Thursday, November 5, 2026. To access the replay, please dial 1-844-512-2921, or 1-412-317-6671 for international participants, and reference pass code 13762493.

About Getty Realty Corp.

Getty Realty Corp. is a publicly traded, net lease REIT specializing in the acquisition, financing and development of convenience, automotive and other single tenant retail real estate. As of September 22, 2026, the Company’s portfolio included 1,269 freestanding properties located in 46 states across the United States and Washington, D.C.

Contacts:		Investor Relations
		(646) 349-0598
		ir@gettyrealty.com

• New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer
• Findings are expected to inform a refined Phase 3 development strategy

BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that new pre-specified analyses from the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P in resected pancreatic ductal adenocarcinoma (“PDAC”) have been selected for a late-breaking Proffered Paper oral presentation at the European Society for Medical Oncology (“ESMO”) Congress 2026, being held October 23–27, 2026, in Madrid, Spain.

“We are pleased to share the complete AMPLIFY-7P results, including new late-breaking analyses, with the global oncology community at ESMO Congress 2026,” said Robert Connelly, President and Chief Executive Officer of Elicio. “These findings deepen our understanding of ELI-002 7P’s clinical and biological activity and provide important direction as we refine the development strategy for a potential Phase 3 study in adjuvant pancreatic cancer.”

Proffered Paper Presentation Details

Abstract Number: LBA83
Title: Seven-Valent mKRAS-specific Lymph Node Targeted Amphiphile Immunotherapy Versus Observation in Resected Pancreatic Ductal Adenocarcinoma (PDAC): the AMPLIFY-7P randomized Phase 2 study
Presenter: Eileen M. O’Reilly, M.D., Memorial Sloan Kettering Cancer Center
Date and Time: October 23, 2026, 13:30-15:00 PM, CEST / 7.30-9 AM EST
Location: Almeria Auditorium- Hall 9

The late-breaking abstract will be available via the ESMO Congress 2026 website beginning at 00:05 CEST on October 23, 2026, the day of the presentation. Subject to presenter permission, a webcast of the session will be available on ESMO Congress 2026 Virtual Platform within 12 hours following the session.

About the AMPLIFY-7P Phase 2 Study

AMPLIFY-7P is a randomized Phase 2 study evaluating ELI-002 7P versus observation in patients with mKRAS-driven PDAC following completion of standard therapy. The study enrolled 144 patients across 24 U.S. clinical sites.

While the study did not meet its pre-specified primary disease-free survival (“DFS”) endpoint in the intent-to-treat population, subsequent analyses have provided important insights into the clinical and biological activity of ELI-002 7P and informed the Company’s continued evaluation of the program.

At ESMO Congress 2026, Elicio will present new pre-specified analyses from AMPLIFY-7P that provide additional insights into the potential clinical benefit of ELI-002 7P and are expected to further inform the Company’s refined Phase 3 development strategy in adjuvant pancreatic cancer.

About ELI-002

Elicio’s lead product candidate, ELI-002, is a structurally novel investigational Amphiphile (“AMP”) cancer immunotherapy that targets cancers driven by mutations in the KRAS gene, a prevalent driver of many human cancers. ELI-002 is comprised of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant, and is available as an off-the-shelf subcutaneous administration.

ELI-002 7P, the seven-peptide formulation, was evaluated in the randomized Phase 2 AMPLIFY-7P trial in patients with mKRAS-driven pancreatic cancer. The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present across multiple solid tumors.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies.

Elicio’s AMP technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors.

Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing and rapid availability of drug to patients, especially in neoadjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches.

Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively.

For more information, please visit www.elicio.com.

Elicio Cautionary Note on Forward-Looking Statements

Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA.

These include statements regarding the timing and content of Elicio’s presentation at ESMO Congress 2026; the clinical activity, therapeutic potential and potential benefits of ELI-002 7P; the interpretation and potential implications of results and analyses from the AMPLIFY-7P study; the potential for new pre-specified analyses to further characterize the clinical activity of ELI-002 7P; the potential for such analyses and the totality of AMPLIFY-7P findings to inform or support a refined Phase 3 development strategy; the potential benefits and effectiveness of off-the-shelf immunotherapy approaches; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them.

No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.

Elicio uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify forward-looking statements intended to be covered by the safe-harbor provisions of the PSLRA.

Such forward-looking statements are based on Elicio’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio’s plans to develop and commercialize its product candidates, including ELI-002; the timing of the availability and presentation of data from Elicio’s clinical trials; Elicio’s plans to research, develop and commercialize its current and future product candidates; the design and timing of future clinical trials; and Elicio’s estimates regarding future revenue, expenses, capital requirements and need for additional financing.

New factors emerge from time to time, and it is not possible for Elicio to predict all such factors, nor can Elicio assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

These risks are more fully discussed under the heading “Risk Factors” in Elicio’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026, as amended on April 29, 2026, and Elicio’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 11, 2026, and Elicio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026 , as updated by subsequent reports and other documents filed from time to time with the SEC.

Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.

Elicio Investor Relations Contact

Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

ANDOVER, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, will hold a conference call on Thursday, October 8, 2026 at 9:00 a.m. Eastern time to discuss its financial results for the fiscal third quarter ended August 31, 2026. Financial results will be issued in a press release prior to the call.

Byrna management will host the presentation, followed by a question-and-answer period.

Date: Thursday, October 8, 2026
Time: 9:00 a.m. Eastern time
Toll-Free Dial-In: 877-709-8150
International Dial-In: +1 201-689-8354
Conference ID: 13762670

Please call the conference telephone number 10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 949-574-3860.

The conference call will be broadcast live and available for replay here and via the Investor Relations section of Byrna’s website.

About Byrna Technologies Inc.
Byrna is a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions. For more information on the Company, please visit the corporate website here or the Company’s investor relations site here. The Company is the manufacturer of the Byrna^® CL, Byrna^® LE, and Byrna^® SD personal security devices, state-of-the-art handheld CO2 powered launchers designed to provide a less-lethal alternative to a firearm for the consumer, private security, and law enforcement markets. To purchase Byrna products, visit the Company’s e-commerce store.

Investor Contact:
Tom Colton and Greg Bradbury
Gateway Group, Inc.
949-574-3860
BYRN@gateway-grp.com